Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5577 - Safety and Efficacy of the PD-1 Inhibitor ABBV-181 in Patients with Advanced Solid Tumors: Preliminary Phase 1 Results from Study M15-892

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Presenters

John Powderly

Citation

Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279

Authors

J. Powderly1, P.A. Cassier2, A. Cervantes3, B. Gao4, A. Gazzah5, A. Italiano6, C. Lin7, J.J. Luke8, V. Moreno9, K. Peltola10, D. Rasco11, A.I. Spira12, M.M.E. Tanner13, D. Tosi14, D. Afar15, S. Englert15, A. Parikh15, A. Reddy15, G. Vosganian15, A.W. Tolcher16

Author affiliations

  • 1 Founder, Carolina Biooncology Cancer Therapy, 28078 - Huntersville/US
  • 2 Department Of Medicine, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 4 Medical Oncology, The Crown Princess Mary Cancer Centre, 2145 - Westmead/AU
  • 5 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 6 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 7 Department Of Oncology, National Taiwan University Hospital, 100 - Taipei city/TW
  • 8 Medical Oncology, The University of Chicago Medical Centre, 60637-1470 - Chicago/US
  • 9 Medical Oncology-start Madrid-fjd, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 10 Trial Unit, Helsinki University Central Hospital, 00029 - Helsinki/FI
  • 11 Medical Oncology, START, San Antonio/US
  • 12 ,, Virginia Cancer Specialists, Fairfax/US
  • 13 Medical Oncology, Tampere University Hospital (Tays), 33521 - Tampere/FI
  • 14 Medical Oncology, Institut du Cancer de Montpellier, 34290 - Montpellier/FR
  • 15 Oncology, AbbVie Inc., Redwood City/US
  • 16 Clinical research, NEXT OncologyTM, San Antonio/US
More

Resources

Abstract 5577

Background

ABBV-181 is a humanized, recombinant, IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1), incorporating an Fc mutation to limit FcgR-mediated effector function. Here we present preliminary ABBV-181 monotherapy data.

Methods

Patients (pts) with previously treated advanced solid tumors received ABBV-181 to progression at 1, 3, or 10 mg/kg IV Q2W (3 + 3 dose finding phase). Following dose finding, multi-histology, non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC) cohorts were opened. Dose limiting toxicities (DLTs) were assessed on days 1-28 of dose finding focused on immune mediated (IM) events, hemolysis, and cytopenia. Response is assessed Q8W per response evaluation criteria in solid tumors (RECIST v.1.1) and immune RECIST.

Results

As of January 15, 2018, 53 pts were treated with ABBV-181: 25 in dose finding, 17, 6, and 5 in multi-histology, HNSCC and NSCLC cohorts, respectively. Median age was 61 (range 27-84) years, 41% male, most frequent diagnoses in dose finding and multi-histology: cholangio, ovarian, breast and cervical carcinoma. Median days on study were 43 (range 1-379), 42 (79%) pts had ≥ 1 adverse event (AE), 22 pts (42%) had grade ≥ 3 AEs and 8 (15%) pts had IM AEs. The most frequent AEs of any grade were: fatigue (18 pts), constipation and vomiting (9 pts each). No DLTs were reported. ABBV-181 was discontinued in 33 (62%) pts, 27 for progression and 1 each for AEs of diabetic ketoacidosis, progression and small intestinal obstruction. PD-L1 was expressed on 7/21 (33%) available pretreatment samples (Dako 28-8 assay with 1% threshold). By investigator assessment, 4/34 (12%) pts with post baseline assessment responded (all in dose finding, all partial responses). Sustained PD-1 saturation on circulating CD4 T cells was observed at all doses. ABBV-181 pharmacokinetics (PK) were approximately dose-proportional in dose finding.

Conclusions

ABBV-181 monotherapy demonstrates target engagement and encouraging efficacy without unexpected safety signals. PK and pharmacodynamic data from dose finding support flat doses of 250 mg Q2W, 375 mg Q3W or 500 mg Q4W for expansion. Enrollment in the expansion cohorts continues.

Clinical trial identification

NCT03000257.

Legal entity responsible for the study

AbbVie Inc.

Funding

AbbVie Inc.

Editorial Acknowledgement

Disclosure

P.A. Cassier: Honoraria: Novartis, Roche-Genentech, Blueprint Medicines, Amgen; Institution research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck, Sharp and Dohme. K. Peltola: Advisory fees: Orion Pharma, BMS, MSD, Pfizer, Ipsen and Roche; Stock holder: Faron Pharmaceuticals. A.I. Spira: Consultant and institutional research support: AbbVie. M.M.E. Tanner: Finnish advisory board: Roche, Novartis, Pfizer; Speakers bureau: Roche, Novartis, Pfizer, Amgen. D. Afar, S. Englert, A. Parikh, A. Reddy, G. Vosganian: Employee and may own stock: AbbVie. A.W. Tolcher: Consultant: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.